Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis

Journal of Crohn's and Colitis

Volumn 10, Issue 3, 2016, Pages 330-337

  Kevans, D ^a,b   Tyler, A D ^a   Holm, K ^c   Jorgensen K K ^c,d   Vatn, M H ^e   Karlsen, T H ^c   Kaplan, G G ^f   Eksteen, B ^f   Gevers, D ^g   Hov, J R ^c   Silverberg, Mark S ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF CALGARY   (Canada)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Intestinal microbiota; Next generation sequencing; PSC

Indexed keywords

MESALAZINE; RNA 16S;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOSCOPIC BIOPSY; FEMALE; FLAVOBACTERIA; GENUS; HUMAN; HUMAN TISSUE; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; NEXT GENERATION SEQUENCING; PHENOTYPE; PRIMARY SCLEROSING CHOLANGITIS; PRINCIPAL COORDINATE ANALYSIS; PRIORITY JOURNAL; PSEUDOMONAS; QUANTITATIVE ANALYSIS; TAXONOMY; ULCERATIVE COLITIS; UNIVERSITY HOSPITAL; ADOLESCENT; BIODIVERSITY; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; COMPLICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PRINCIPAL COMPONENT ANALYSIS; SCLEROSING CHOLANGITIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIODIVERSITY; CASE-CONTROL STUDIES; CHILD; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; YOUNG ADULT;

EID: 84963852038     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv204     Document Type: Article

References (22)

1. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904.
2. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014;15:382-92.
3. Gill N, Finlay BB. The gut microbiota: challenging immunology. Nat Rev Immunol 2011;11:636-7.
4. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013;382:158-799.
5. Chapman R, Fevery J, Kalloo A, et al. American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78.
6. Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011;53:1590-9.
7. Liu JZ, Hov JR, Folseraas T, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013;45:670-5.
8. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991;13:766-72.
9. Sinakos E, Lindor K. Treatment options for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol 2010;4:473-88.
10. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19:5A-36A.
11. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007;102:1042-9.
12. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010;7:335-6.
13. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010;26:2460-1.
14. Moreno CE, Rodriguez P. A consistent terminology for quantifying species diversity? Oecologia 2010;163:279-82.
15. Lozupone CA, Hamady M, Kelley ST, Knight R. Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities. Appl Environ Microbiol 2007;73:1576-85.
16. Tabibian JH, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int 2013;2013:389537.
17. Rossen NG, Fuentes S, Boonstra K, et al. The musosa-associated micro-biota of PSC patients is characterized by a low diversity and a low abundance of uncultured Clostridiales II. J Crohns Colitis 2015;9:342-8.
18. Tyler AD, Smith MI, Silverberg MS. Analyzing the human microbiome: a 'how to' guide for physicians. Am J Gastroenterol 2014;109:983-93.
19. Hildebrand F, Nguyen TL, Brinkman B, et al. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol 2013;14:R4.
20. Franzosa EA, Morgan XC, Segata N, et al. Relating the metatranscriptome and metagenome of the human gut. Proc Natl Acad Sci U S A 2014;111:E2329-38.
21. Huttenhower C, Knight R, Brown CT, et al. Advancing the microbiome research community. Cell 2014;159:227-30.
22. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014;40:843-54.